Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis

Dong,Zhaogang; Du,Lutao; Xu,Xiaofei; Yang,Yongmei; Wang,Haiyan; Qu,Ailin; Qu,Xun; Wang,Chuanxin

doi:10.3892/ijmm.2013.1287

Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis

Authors:
- Zhaogang Dong
- Lutao Du
- Xiaofei Xu
- Yongmei Yang
- Haiyan Wang
- Ailin Qu
- Xun Qu
- Chuanxin Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Institute of Basic Medical Sciences, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/ijmm.2013.1287
Pages: 989-997

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease, yet its etiology and pathogenesis remain poorly understood. The aberrant expression of T lymphocytes plays an essential role in the progression of UC. This study aimed to evaluate the expression profile of circulating Th17, Th1 and Tc1 cells in patients with active and inactive UC. Our results revealed that the percentage of circulating Th17 cells (CD3+CD8-IL-17+) was significantly increased in patients with active UC when compared with the percentage in patients with inactive UC, Crohn's disease (CD) and healthy controls. The percentages of circulating Th1 (CD3+CD8-IFN-γ+) and Tc1 (CD3+CD8+IFN-γ+) cells were also higher in patients with active UC when compared with the percentages in patients with inactive UC and normal controls, although levels were lower than that in CD. Further analysis showed that Th17 cells were positively correlated with Th1 cells, but not with Tc1 cells. Notably, the three cells had a positive correlation with disease activity, extent of disease, detection of erythrocyte sedimentation rate and c-reactive protein in active UC. Moreover, plasma IL-17 was higher in patients with active UC, and a similar trend applied to the mRNA levels of RORγt and T-bet in peripheral blood mononuclear cells (PBMCs). The levels of p-STAT3 and p-STAT5 in PBMCs, as well as the ratio of p-STAT3/p-STAT5, were also elevated in active UC patients. Taken together, our findings revealed that elevated circulating Th17, Th1 and Tc1 cells and the aberrant activation of the STAT pathway may be implicated in the progression of UC. These findings may provide preliminary experimental clues for the development of new therapies for UC.

View Figures

View References

1	Wang YF, Ouyang Q and Hu RW: Progression of inflammatory bowel disease in China. J Dig Dis. 11:76–82. 2010. View Article : Google Scholar : PubMed/NCBI
2	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
3	Choi PM and Zelig MP: Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 35:950–954. 1994.
4	Targan SR and Karp LC: Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 206:296–305. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ishiguro Y: Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol. 34:66–74. 1999. View Article : Google Scholar : PubMed/NCBI
6	Strober W and Fuss IJ: Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 140:1756–1767. 2011. View Article : Google Scholar : PubMed/NCBI
7	Melgar S, Yeung MM, Bas A, et al: Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 134:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
8	Strober W, Fuss IJ and Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol. 20:495–549. 2002. View Article : Google Scholar : PubMed/NCBI
9	Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J and Goll R: Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 47:538–547. 2012. View Article : Google Scholar : PubMed/NCBI
10	Komatsu M, Kobayashi D, Saito K, et al: Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 47:1297–1301. 2001.PubMed/NCBI
11	Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K and Okita K: Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol. 37:345–353. 2002. View Article : Google Scholar
12	Olsen T, Goll R, Cui G, et al: Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 42:1312–1320. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bernardo D, Vallejo-Díez S, Mann ER, et al: IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol. 42:1337–1353. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rovedatti L, Kudo T, Biancheri P, et al: Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 58:1629–1636. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhang J, Ma D, Zhu X, Qu X, Ji C and Hou M: Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 94:1326–1329. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Li JM, Liu XG, et al: Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol. 31:606–614. 2011. View Article : Google Scholar : PubMed/NCBI
17	Harrington LE, Hatton RD, Mangan PR, et al: Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005.PubMed/NCBI
18	Park H, Li Z, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
19	Monteleone I, Pallone F and Monteleone G: Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Ann Med. 43:172–178. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bettelli E, Korn T, Oukka M and Kuchroo VK: Induction and effector functions of T(H)17 cells. Nature. 453:1051–1057. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ivanov II, McKenzie BS, Zhou L, et al: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17⁺ T helper cells. Cell. 126:1121–1133. 2006. View Article : Google Scholar : PubMed/NCBI
22	Li Y, de Haar C, Chen M, et al: Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 59:227–235. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bi Y and Yang R: Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions. Scand J Immunol. 75:543–552. 2012. View Article : Google Scholar : PubMed/NCBI
24	Monteleone I, Pallone F and Monteleone G: Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med. 9:1222011. View Article : Google Scholar : PubMed/NCBI
25	Li F, Zou Y and Li X: Up-regulation of signal transducer and activator of transcription-3 is associated with aggravation of ulcerative colitis. Surgeon. 8:262–266. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sandborn WJ and Faubion WA: Biologics in inflammatory bowel disease: how much progress have we made? Gut. 53:1366–1373. 2004. View Article : Google Scholar : PubMed/NCBI
27	Sands BE: From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 126:1518–1532. 2004. View Article : Google Scholar : PubMed/NCBI
28	Schroeder KW, Tremaine WJ and Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 317:1625–1629. 1987. View Article : Google Scholar : PubMed/NCBI
29	Hart AL, Kamm MA, Knight SC and Stagg AJ: Prospective evaluation of intestinal homing memory T cells in ulcerative colitis. Inflamm Bowel Dis. 10:496–503. 2004. View Article : Google Scholar : PubMed/NCBI
30	Bitton A, Peppercorn MA, Antonioli DA, et al: Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 120:13–20. 2001. View Article : Google Scholar : PubMed/NCBI
31	Ge J, Wang K, Meng QH, Qi ZX, Meng FL and Fan YC: Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol. 30:60–67. 2010. View Article : Google Scholar : PubMed/NCBI
32	Pelchen-Matthews A, Parsons IJ and Marsh M: Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med. 178:1209–1222. 1993. View Article : Google Scholar
33	Yang XP, Ghoreschi K, Steward-Tharp SM, et al: Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 12:247–254. 2011. View Article : Google Scholar : PubMed/NCBI
34	Laurence A, Tato CM, Davidson TS, et al: Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 26:371–381. 2007. View Article : Google Scholar : PubMed/NCBI
35	Kolls JK and Lindén A: Interleukin-17 family members and inflammation. Immunity. 21:467–476. 2004. View Article : Google Scholar : PubMed/NCBI
36	Ohta N, Makihara S, Okano M, et al: Roles of IL-17, Th1, and Tc1 cells in patients with IgG4-related sclerosing sialadenitis. Laryngoscope. 122:2169–2174. 2012. View Article : Google Scholar : PubMed/NCBI
37	Olsen T, Rismo R, Cui G, Goll R, Christiansen I and Florholmen J: TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 56:633–640. 2011. View Article : Google Scholar : PubMed/NCBI
38	Turner D, Mack DR, Hyams J, et al: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis. 5:423–429. 2011. View Article : Google Scholar : PubMed/NCBI
39	Dong C: TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 8:337–348. 2008. View Article : Google Scholar : PubMed/NCBI
40	Leppkes M, Becker C, Ivanov II, et al: RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 136:257–267. 2009. View Article : Google Scholar : PubMed/NCBI
41	Boniface K, Blumenschein WM, Brovont-Porth K, et al: Human Th17 cells comprise heterogeneous subsets including IFN-γ-producing cells with distinct properties from the Th1 lineage. J Immunol. 185:679–687. 2010.PubMed/NCBI
42	Garg SK, Voelmle MK, Beatson CR, et al: Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 34:574–579. 2011. View Article : Google Scholar
43	Johnston RJ, Choi YS, Diamond JA, Yang JA and Crotty S: STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med. 209:243–250. 2012. View Article : Google Scholar : PubMed/NCBI
44	Fujino S, Andoh A, Bamba S, et al: Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
45	Bisping G, Lugering N, Lutke-Brintrup S, et al: Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8⁺ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol. 123:15–22. 2001. View Article : Google Scholar : PubMed/NCBI
46	Kamikozuru K, Fukunaga K, Hirota S, et al: The expression profile of functional regulatory T cells, CD4⁺CD25^high+/forkhead box protein P3⁺, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol. 156:320–327. 2009.PubMed/NCBI